|Synonyms||MIN-202; JNJ-42847922; JNJ-922|
|Chemical and physical data|
|Molar mass||407.443 g/mol g·mol−1|
|3D model (JSmol)|
Seltorexant (former developmental code names MIN-202, JNJ-42847922, JNJ-922) is a selective, small-molecule antagonist of the OX2 receptor that is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceutica for the treatment of insomnia and major depressive disorder (MDD). As of December 2015, it is in phase II clinical trials for both insomnia and MDD.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|